Medtronic Banking On Gene Therapy For Drug-Coated Stents With AVI Deal
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's drug-coated stent development program is using an unapproved antisense compound, Resten-NG, licensed from AVI BioPharma.
You may also be interested in...
PercuSurge GuardWire Associated With Fewer Adverse Cardiac Events
A comparatively low rate of major adverse cardiac events (MACE) in patients treated with Medtronic/PercuSurge's GuardWire distal protection device during saphenous vein graft repair procedures contributed to a favorable FDA panel review, despite concerns about the device's malfunction rate.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.